ExacTrac SV system allows precise targeting of radiotherapy using real-time X-ray images

2nd European Lung Cancer Conference

A system that allows precise targeting of radiotherapy using real-time X-ray images has allowed French doctors to increase the dose of radiation they administered to lung and liver cancers while minimizing harm to nearby healthy tissue, researchers report at the 2nd European Lung Cancer Conference.

"With this study we show that it is possible and very important to have a precise system that can give information at any time before or during treatment in terms of patient condition, technical issues and treatment duration, always maintaining the accuracy and safety of the irradiation," said Dr Corina Udrescu from Centre Hospitalier Lyon Sud, who presented the data at the conference.

The system tested by the French researchers was ExacTrac SV, which uses X-ray images acquired at any moment during treatment delivery to visualize tumors that move or change size and shape during radiotherapy treatment.

"The ultimate aim is to precisely irradiate the target, and protect the surrounding tissues from radiation as much as possible," Dr Udrescu said. "Then we get the optimal ratio of tumor benefit to normal tissue damages."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Immunotherapy yields complete response in stage IV lung cancer